VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FTHFaeth Therapeutics, Inc.
$9.04$568M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFTHFinancials

Faeth Therapeutics, Inc. (FTH) Income Statement

8Y historyFree accessUpdated daily

The company remains a pre-revenue entity, with R&D expenses consistently consuming the majority of capital, as seen in the $18.0 million R&D spend during 2026Q1.

Income StatementBalance SheetCash FlowRatios

FTH Income Statement

Annual statement

FTH Income Statement

Faeth Therapeutics, Inc. (FTH) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue000000000
Revenue Growth %100%--------
Cost of Goods Sold132.97M0551K571K1.81M685K209K73K44K
COGS % of Revenue---------
Gross Profit-132.97M0-551K-571K-1.81M-685K-209K-73K-44K
Gross Margin %---------
Gross Profit Growth %-100%3.5%68.42%-163.94%-227.75%-186.3%-65.91%-
Operating Expenses83.1M22.29M31.11M36.49M47.31M36.8M19.24M12.36M12.74M
OpEx % of Revenue---------
Selling, General & Admin42.06M11.33M12.48M18.77M17.73M15.13M7.53M4.01M4.51M
SG&A % of Revenue---------
Research & Development41.04M10.96M18.63M18.3M29.58M21.66M11.92M8.35M8.23M
R&D % of Revenue---------
Other Operating Expenses000-571K00-209K028K
Operating Income-216.06M-22.29M-31.66M-37.06M-49.12M-37.48M-19.45M-12.44M-12.74M
Operating Margin %---------
Operating Income Growth %-29.61%14.57%24.54%-31.05%-92.7%-56.42%2.39%-
EBITDA-215.95M-22.15M-30.34M-35.71M-47.77M-36.8M-19.24M-12.36M-12.7M
EBITDA Margin %---------
EBITDA Growth %-791.69%27%15.04%25.24%-29.83%-91.23%-55.65%2.63%-
D&A (Non-Cash Add-back)105K139K1.32M1.35M1.35M685K209K73K44K
EBIT-213.04M-21.05M-30.07M-36.96M-48.37M-36.12M-18.41M-14.48M-12.71M
Net Interest Income4.65M1.21M2.46M3.48M1.56M130K-1.69M-2.25M0
Interest Income4.65M1.24M2.55M3.62M1.78M800K1.69K2.26K0
Interest Expense3K32K90K144K219K670K1.69M2.26M327K
Other Income/Expense4.7M1.2M1.51M2.96M532K688K-649K-4.3M-299K
Pretax Income-211.36M-21.09M-30.16M-34.1M-48.59M-36.79M-20.1M-16.74M-13.04M
Pretax Margin %---------
Income Tax000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%
Net Income-211.36M-21.09M-30.16M-34.1M-48.59M-36.79M-20.1M-16.74M-13.04M
Net Margin %---------
Net Income Growth %-775.59%30.08%11.57%29.82%-32.05%-83.05%-20.07%-28.38%-
Net Income (Continuing)-211.36M-21.09M-30.16M-34.1M-48.59M-36.79M-20.1M-16.74M-13.04M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)-8.18-16.72-24.01-24.40-31.65-26.56-13.21-14.01-11.49
EPS Growth %-624.53%30.36%1.6%22.91%-19.16%-101.06%5.71%-21.93%-
EPS (Basic)--16.72-24.01-24.40-31.65-26.56-13.21-14.01-11.49
Diluted Shares Outstanding25.84M1.26M1.26M1.4M1.54M1.39M1.53M1.47M1.47M
Basic Shares Outstanding25.84M1.26M1.26M1.4M1.54M1.39M1.53M1.47M1.47M
Dividend Payout Ratio---------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and clinical binary

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Absence of Commercial Revenue Streams

As indicated by the company's financial statements, Sensei Biotherapeutics remains a pre-revenue entity, with no recurring income streams to offset its ongoing research expenditures, leaving the firm entirely dependent on external capital markets to fund its clinical development pipeline and general corporate operations moving forward.

The lack of revenue generation is consistent with the company's current stage as a clinical-stage biotechnology firm. Investors should note that the absence of top-line growth underscores the binary nature of the investment, where value is derived solely from clinical trial milestones rather than operational performance.

Fixed Cost Burden Remains Elevated

Based on reported figures, the company maintains a high fixed-cost structure primarily driven by R&D activities, with quarterly research expenses consistently consuming the majority of available capital, which suggests a limited operational runway without immediate access to additional dilutive financing or strategic partnership capital inflows.

The persistent R&D spend reflects the intensive nature of managing the SNS-101 Phase 1/2 clinical trial. This cost structure appears rigid, as the company lacks the scale to absorb these expenses, necessitating a high degree of fiscal discipline to avoid further erosion of the remaining cash position.

Distorted Net Loss and Volatility

According to recent SEC filings, the reported net loss figures are significantly impacted by non-cash items and lumpy clinical trial accruals, which complicates the assessment of the company's underlying burn rate and obscures the true economic cost of its ongoing research and development initiatives.

The presence of stock-based compensation and irregular clinical trial expenses suggests that headline net income figures may not accurately reflect the company's cash-based operational efficiency. Analysts should monitor these adjustments closely to determine the actual rate at which the company is consuming its limited liquidity.

Liquidity Constraints Threaten Operational Continuity

As reported in financial statements, the company's cash position of $8,668,000 creates a precarious liquidity profile, which suggests that the firm may face significant challenges in sustaining its current clinical trial trajectory without an immediate and potentially dilutive capital raise to address its funding gap.

The current cash balance appears insufficient to support long-term clinical development, raising concerns about the company's ability to reach critical data readouts. This liquidity risk warrants further investigation into the potential for a strategic transaction or a restructuring of the current research pipeline to preserve capital.

FTH — Frequently Asked Questions

Quick answers to the most common questions about buying FTH stock.

What was Faeth Therapeutics, Inc.'s (FTH) revenue in 2025?

For fiscal year 2025, Faeth Therapeutics, Inc. (FTH) reported total revenue of $0.0M.

Is Faeth Therapeutics, Inc. (FTH) profitable?

Faeth Therapeutics, Inc. (FTH) reported a net loss of $21.1M for the fiscal year ending 2025.